International Clinical Trial: OPPS-2071 for the treatment of IBS-D

Geneva, Aug. 17 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129705) titled 'OPPS-2071 for the treatment of IBS-D' on Aug. 7.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Condition: Irritable Bowel Syndrome with Diarrhea (IBS-D)

Intervention: placebo group:placebo Medium-dose drug group:OPS-2071 100 mg/bid High-dose drug group:OPS-2071 200 mg/bid

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2023-09-21

Target Sample Size: placebo group:20;Medium-dose drug group:20;High-dose drug group:20;Low-dose drug group:20;

Countries of Recruitment:...